14 Jun 2016 12:18
Venture Life Group PLC
("Venture Life" or the "Company")
Director/PDMR Shareholding
Bracknell, UK - 14 June 2016: Venture Life Group plc (AIM: VLG), the international consumer healthcare group addressing the self-care needs of the ageing population, announces that it was informed on 13 June 2016 that Ms. Sharon Collins, the Commercial Director of the Company, has undertaken dealings in 27,030 ordinary shares of 0.3p each in the Company ("Ordinary Shares"), transferring 26,430 of her current holding of Ordinary Shares to her ISA, and selling and re-purchasing 600 Ordinary Shares to be held in her non-ISA account.
The dealings were made between 8 June 2016 and 13 June 2016 as set out below:
Date | Dealing type | Number of Ordinary Shares sold | Number of Ordinary Shares purchased | Price (p) |
8 June 2016 | Sale | 26,600 | - | 57.00 |
8 June 2016 | Purchased to ISA | - | 26,000 | 57.10 |
9 June 2016 | Sale | 430 | - | 57.00 |
9 June 2016 | Purchased to ISA | - | 430 | 57.00 |
Total sold | 27,030 | - |
| |
Total purchased to ISA | - | 26,430 |
| |
|
|
|
|
|
13 June 2016 | Purchase | - | 600 | 59.49 |
Total dealings | 27,030 | 27,030 |
| |
Following the dealings, Ms. Collins's beneficial interest in the Company remains unchanged at 1,582,417 Ordinary Shares, representing approximately 4.3% of the issued share capital in the Company.
For further information please contact:
Venture Life Group PLC
Jerry Randall, Chief Executive Officer +44 (0)1344 742 870
James Hunter, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser and Broker) Freddy Crossley +44 (0) 20 7886 2500
Peter Steel
Duncan Monteith Corporate Finance
Tom SalvesenCorporate Broking
Square1 Consulting
David Bick
Brian Alexander +44 (0)20 7929 5599
About Venture Life
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.
The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
Venture Life (VLG)